Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
The Development Center with its state-of-the art laboratories and flexible pilot capacities is set to become Siegfried's global research and development hub for its Drug Products sites, strengthening the global network
The new site enables end-to-end production of viral vector gene therapies
The centre has an initial capacity of 500 FTEs
Subscribe To Our Newsletter & Stay Updated
